CN111973678A - Navel treatment medicine for treating damp-heat collateral obstruction type chronic prostatitis - Google Patents
Navel treatment medicine for treating damp-heat collateral obstruction type chronic prostatitis Download PDFInfo
- Publication number
- CN111973678A CN111973678A CN202010922464.3A CN202010922464A CN111973678A CN 111973678 A CN111973678 A CN 111973678A CN 202010922464 A CN202010922464 A CN 202010922464A CN 111973678 A CN111973678 A CN 111973678A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- mixture
- weight
- radix
- fluid extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 40
- 208000013507 chronic prostatitis Diseases 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 34
- JHGWQSGWUPCKNT-UHFFFAOYSA-N 2-tert-butyl-4-methyl-1,3,5-trinitrobenzene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C(C)(C)C)=C1[N+]([O-])=O JHGWQSGWUPCKNT-UHFFFAOYSA-N 0.000 claims abstract description 21
- 241000218176 Corydalis Species 0.000 claims abstract description 21
- 239000004863 Frankincense Substances 0.000 claims abstract description 20
- 239000000052 vinegar Substances 0.000 claims abstract description 20
- 235000021419 vinegar Nutrition 0.000 claims abstract description 20
- 241000241125 Gryllotalpa gryllotalpa Species 0.000 claims abstract description 14
- 241000545744 Hirudinea Species 0.000 claims abstract description 14
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 13
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 12
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 12
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 12
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 12
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 12
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 12
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 12
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 11
- 241000241550 Cyathula Species 0.000 claims abstract description 11
- 241000218691 Cupressaceae Species 0.000 claims abstract description 7
- 241000246044 Sophora flavescens Species 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000012530 fluid Substances 0.000 claims description 26
- 238000002156 mixing Methods 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 17
- 241000717739 Boswellia sacra Species 0.000 claims description 12
- 241000219061 Rheum Species 0.000 claims description 12
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 8
- 241001057584 Myrrha Species 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 8
- 241001243091 Gryllotalpa Species 0.000 claims description 6
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 6
- 241000237903 Hirudo Species 0.000 claims description 6
- 241000972672 Phellodendron Species 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 240000007551 Boswellia serrata Species 0.000 abstract description 8
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 230000036407 pain Effects 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 208000002193 Pain Diseases 0.000 description 25
- 201000010099 disease Diseases 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 238000000034 method Methods 0.000 description 12
- 230000027939 micturition Effects 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 8
- 239000000787 lecithin Substances 0.000 description 8
- 229940067606 lecithin Drugs 0.000 description 8
- 235000010445 lecithin Nutrition 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 210000002307 prostate Anatomy 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 206010042674 Swelling Diseases 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 239000011505 plaster Substances 0.000 description 6
- 230000008736 traumatic injury Effects 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 239000013256 coordination polymer Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000004197 pelvis Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000402754 Erythranthe moschata Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 244000183278 Nephelium litchi Species 0.000 description 2
- 235000015742 Nephelium litchi Nutrition 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010033372 Pain and discomfort Diseases 0.000 description 2
- 208000008350 Pruritus Vulvae Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 241000207929 Scutellaria Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000003903 pelvic floor Anatomy 0.000 description 2
- 210000002640 perineum Anatomy 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 210000004706 scrotum Anatomy 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010000097 Abdominal tenderness Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 206010039954 Seminal vesiculitis Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043345 Testicular pain Diseases 0.000 description 1
- 206010043354 Testicular swelling Diseases 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010065584 Urethral stenosis Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 201000004822 varicocele Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Animal Husbandry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a navel treatment medicine for treating damp-heat collateral obstruction type chronic prostatitis, which can effectively solve the problem of medicine application for externally treating damp-heat collateral obstruction type prostatitis, and is prepared from the following components in parts by weight: the traditional Chinese medicine composition is prepared from 0.2-0.3g of artificial musk, 8-12g of frankincense, 8-12g of myrrh, 10-14g of scutellaria baicalensis, 10-14g of wine-processed rhubarb, 10-14g of golden cypress, 10-14g of sophora flavescens, 2.5-3.5g of scalded leech, 2.5-3.5g of mole cricket, 13-17g of tangerine seed, 18-22g of vinegar rhizoma corydalis and 11-17g of medicinal cyathula root.
Description
Technical Field
The invention relates to a traditional Chinese medicine, in particular to a navel treatment medicine for treating damp-heat collateral obstruction type chronic prostatitis.
Background
Chronic prostatitis (CP/CPPS) is a clinical syndrome, which is mainly manifested by long-term repeated pain and distending discomfort in the pelvic region, can be accompanied by urination symptoms and sexual dysfunction, often combines certain psychosocial symptoms, and has serious influence on physical and mental health and quality of life of patients, and the National Institutes of Health (NIH) of the united states ranks the chronic prostatitis as one of the most serious chronic diseases affecting the quality of life of residents. At present, the pathogenesis and the occurrence mechanism of the disease are not known, and the disease can be caused by the combined action of a plurality of factors such as pathogen infection, inflammation, urine backflow, abnormal activity of pelvic floor nerve and muscle, immune abnormality, psychopsychological factors and the like.
For the treatment, at present, no better treatment is available, a comprehensive treatment scheme with drugs as main materials and physical therapy as auxiliary materials is adopted, and conventional drugs comprise antibiotics, a-receptor blockers, nonsteroidal anti-inflammatory analgesics, anxiolytic drugs and the like, but the effect is not ideal.
In recent years, in the aspect of treating the disease by traditional Chinese medicines, more intensive research is carried out, and good clinical curative effect and development prospect are shown, but mainly oral Chinese patent medicines are taken, and in view of the characteristics of the disease, patients need to take medicines for a long time, so that not only the gastrointestinal tract is stimulated, but also liver injury is possibly caused, and a certain number of patients cannot insist on using the medicine, and the clinical curative effect is influenced.
Under the guidance of the theory of traditional Chinese medicine, how to fully exert the advantages of traditional Chinese medicine external treatment and develop and research a traditional Chinese medicine external navel treatment patch which has definite curative effect, good safety and convenient carrying and use is always an important technical subject of research in the industry.
Disclosure of Invention
Based on the current research situation, the invention aims to overcome the defects of the prior art and provide the navel treatment medicine for treating the dampness-heat collateral obstruction type chronic prostatitis, and the navel treatment medicine can effectively solve the problem of external application of medicines for treating the dampness-heat collateral obstruction type prostatitis.
The technical scheme of the invention is that the navel treatment medicine for treating the damp-heat collateral obstruction type chronic prostatitis is prepared from the following components in parts by weight: 0.2-0.3g of artificial musk, 8-12g of frankincense, 8-12g of myrrh, 10-14g of scutellaria baicalensis, 10-14g of wine-processed rhubarb, 10-14g of golden cypress, 10-14g of sophora flavescens, 2.5-3.5g of scalded leech, 2.5-3.5g of mole cricket, 13-17g of tangerine seed, 18-22g of vinegar rhizoma corydalis and 11-17g of medicinal cyathula root, wherein the artificial musk is firstly crushed into fine powder for later use; extracting Scutellariae radix, Olibanum, Myrrha, rhizoma corydalis processed with vinegar, and radix et rhizoma Rhei as first mixture with 70% ethanol at room temperature for 2 times, wherein the amount of ethanol added is 4-6 times of the first mixture weight each time, and each time is 2 hr, mixing extractive solutions, recovering ethanol, and concentrating to obtain first fluid extract with relative density of 1.30-1.35 at 60 deg.C; taking cortex phellodendri, radix sophorae flavescentis, leech, mole cricket, tangerine seed and radix cyathulae as a second mixture, adding water to extract for 2 times at room temperature, adding water for 2 hours each time, wherein the amount of the water added is 6-8 times of the weight of the second mixture, combining decoction, filtering, concentrating to a second clear paste with the relative density of 1.30-1.35 at 60 ℃, uniformly mixing the fine powder of artificial musk, the first clear paste and the second clear paste, and adding polyvinyl alcohol and azone according to the conventional method to prepare the patch (the known technology).
The traditional Chinese medicine composition has the advantages of rich raw materials, low cost, simple preparation method, easy production and preparation, convenient application, good effect, external treatment of internal diseases, blood circulation promoting and qi regulating, collateral dredging and pain relieving, heat clearing and dampness removing effects, effective treatment of the damp-heat collateral blocking type chronic prostatitis, great innovation in the medicine for treating the damp-heat collateral blocking type chronic prostatitis, and obvious economic and social benefits.
Detailed Description
The following examples are provided to explain the present invention in detail.
The invention is illustrated in the following examples.
Example 1
The invention relates to a navel treatment medicine for treating damp-heat collateral obstruction type chronic prostatitis, which is prepared from the following components in parts by weight: 0.25g of artificial musk, 10g of frankincense, 10g of myrrh, 12g of scutellaria baicalensis, 12g of wine-processed rhubarb, 12g of phellodendron, 12g of sophora flavescens, 3g of scalded leech, 3g of mole cricket, 15g of tangerine seed, 20g of vinegar rhizoma corydalis and 15g of medicinal cyathula root, wherein the artificial musk is firstly crushed into fine powder for standby; extracting Scutellariae radix, Olibanum, Myrrha, rhizoma corydalis processed with vinegar, and radix et rhizoma Rhei with 70% ethanol at room temperature for 2 times, wherein the first ethanol is 6 times of the first mixture by weight for 2 hr, and the second ethanol is 4 times of the first mixture by weight, mixing the two ethanol extractive solutions, recovering ethanol, and concentrating to obtain first fluid extract with relative density of 1.32 at 60 deg.C; cortex Phellodendri, radix Sophorae Flavescentis, Hirudo, Gryllotalpa, semen Citri Reticulatae, and radix Cyathulae as second mixture, adding water, extracting at room temperature for 2 times, the first time adding water 8 times the weight of the second mixture for 2 hr, the second time adding water 6 times the weight of the second mixture for 2 hr, mixing the two water extractive solutions, filtering, concentrating to obtain second fluid extract with relative density of 1.32 at 60 deg.C, mixing the fine powder of artificial Moschus, the first fluid extract, and the second fluid extract, and adding polyvinyl alcohol and azone to make into patch.
Example 2
The invention relates to a navel treatment medicine for treating damp-heat collateral obstruction type chronic prostatitis, which is prepared from the following components in parts by weight: 0.22g of artificial musk, 11g of frankincense, 9g of myrrh, 13g of scutellaria baicalensis, 11g of wine-processed rhubarb, 13g of phellodendron, 11g of sophora flavescens, 3.3g of scalded leech, 2.7g of mole cricket, 16g of tangerine seed, 19g of vinegar rhizoma corydalis and 16g of medicinal cyathula root, wherein the artificial musk is firstly crushed into fine powder for standby; extracting Scutellariae radix, Olibanum, Myrrha, rhizoma corydalis processed with vinegar, and radix et rhizoma Rhei with 70% ethanol at room temperature for 2 times, wherein the amount of ethanol added is 5 times of the first mixture weight, and the extraction time is 2 hr, mixing the two ethanol extractive solutions, recovering ethanol, and concentrating to obtain first fluid extract with relative density of 1.33 at 60 deg.C; extracting cortex Phellodendri, radix Sophorae Flavescentis, Hirudo, Gryllotalpa, semen Citri Reticulatae, and radix Cyathulae with water at room temperature for 2 times, each time adding water 7 times the weight of the second mixture, each time extracting for 2 hr, mixing the two water extractive solutions, filtering, concentrating to obtain second fluid extract with relative density of 1.33 at 60 deg.C, mixing the fine powder of artificial Moschus, the first fluid extract, and the second fluid extract, adding polyvinyl alcohol and azone, and making into patch.
Example 3
The invention relates to a navel treatment medicine for treating damp-heat collateral obstruction type chronic prostatitis, which is prepared from the following components in parts by weight: 0.28g of artificial musk, 9g of frankincense, 11g of myrrh, 11g of scutellaria baicalensis, 13g of wine rhubarb, 11g of golden cypress, 13g of radix sophorae flavescentis, 2.7g of scalded leech, 3.3g of mole cricket, 14g of tangerine seed, 21g of vinegar rhizoma corydalis and 12g of medicinal cyathula root, wherein the artificial musk is firstly crushed into fine powder for later use; extracting Scutellariae radix, Olibanum, Myrrha, rhizoma corydalis processed with vinegar, and radix et rhizoma Rhei with 70% ethanol at room temperature for 2 times, wherein the first ethanol is 6 times of the first mixture by weight for 2 hr, and the second ethanol is 4 times of the first mixture by weight, mixing the two ethanol extractive solutions, recovering ethanol, and concentrating to obtain first fluid extract with relative density of 1.35 at 60 deg.C; extracting cortex Phellodendri, radix Sophorae Flavescentis, Hirudo, Gryllotalpa, semen Citri Reticulatae, and radix Cyathulae as second mixture with water at room temperature for 2 times, the first time with water amount 8 times of the second mixture for 2 hr, the second time with water amount 6 times of the second mixture for 2 hr, mixing the two water extractive solutions, filtering, concentrating to obtain second fluid extract with relative density of 1.35 at 60 deg.C, mixing the fine powder of Moschus, the first fluid extract, and the second fluid extract, and adding polyvinyl alcohol and azone to make into patch.
In the above medicament, wherein:
artificial musk: is brown powder, has oily and lustrous properties and special fragrance, has the effects of dredging collaterals and relieving pain, and is used for fever unconsciousness, apoplexy with phlegm syncope, qi depression with sudden syncope, central aversion to coma, heart and abdomen pain, swelling and scrofula, sore throat and traumatic injury.
Frankincense: pungent, bitter and warm in nature, entering heart, liver and spleen channels, activating blood circulation, promoting qi circulation, relieving pain, eliminating swelling, and promoting granulation, and can be used for treating thoracic obstruction, cardialgia, epigastric pain, dysmenorrhea, amenorrhea, puerperal stagnation, abdominal pain, rheumatalgia, spasm of tendons and vessels, traumatic injury, carbuncle, swelling, sore and ulcer.
Myrrh: pungent, bitter and neutral in flavor, enter heart, liver and spleen channels, dissipate blood stasis and relieve pain, resolve swelling and promote granulation, and are used for treating chest stuffiness and pains, epigastric pain, dysmenorrhea and amenorrhea, postpartum stasis, abdominal mass and pain, rheumatic arthralgia, traumatic injury, carbuncle, swelling, sore and ulcer and other diseases.
Scutellaria baicalensis: bitter taste and cold nature, enters the channels of lung, gallbladder, spleen, large intestine and small intestine, clears heat and dries dampness, purges fire and detoxifies, stops bleeding, and prevents abortion, and is used for damp warmth, summer dampness, chest distress and nausea, damp heat and fullness, diarrhea and dysentery, jaundice, lung heat cough, high fever and polydipsia, blood heat and hematemesis, carbuncle swelling and sore toxicity, and threatened abortion.
Wine-processed rhubarb: has effects of clearing heat and relaxing bowels, and can be used for treating gastrointestinal sthenic fever stagnation, constipation, abdominal distention, pain and tenderness, high fever, coma and delirium.
Phellodendron bark: bitter taste and cold nature, entering kidney and bladder channels, has the efficacies of clearing heat and drying dampness, purging fire and removing steam, detoxifying and curing sores, and is used for treating damp-heat diarrhea and dysentery, jaundice and dark urine, leukorrhagia and pruritus vulvae, heat stranguria and pain, beriberi flaccidity cramped, bone steaming and internal heat, night sweat, spermatorrhea, sore and ulcer pyogenic infections, eczema and eczema.
Flavescent sophora root: bitter taste and cold nature, which is in the channels of heart, liver, stomach, large intestine and bladder, has the efficacies of clearing heat and drying dampness, killing parasites and promoting urination, and is used for treating dysentery with fever, hematochezia, jaundice anuresis, leucorrhea with reddish discharge, vulva swelling and pruritus vulvae, eczema, skin pruritus, mange and leprosy and externally treating trichomonas vaginitis.
Leech scalding: salty and bitter in taste, neutral in nature, entering liver channel, has the effects of breaking blood and stimulating menstrual flow, and removing blood stasis and eliminating symptoms, and is used for treating amenorrhea due to blood stasis, addiction to abdominal mass, apoplexy, hemiplegia and traumatic injury.
Mole cricket: salty taste and cold nature, entering stomach and bladder meridians, it has the actions of inducing diuresis and relaxing bowels, and can be used to treat edema, stranguria with stone, dysuria, scrofula, carbuncle, swelling and sore.
Orange seed: bitter taste and neutral nature, enters liver and kidney meridians, has the effects of regulating qi, resolving masses and relieving pain, and is used for treating intestinal hernia, testicular swelling and pain, and mammary abscess swelling and pain.
Vinegar rhizoma corydalis: warm in nature, pungent and bitter in flavor; entering liver and spleen meridians, the main function is: promoting blood circulation, activating qi-flowing, and relieving pain. Can be used for treating pain in chest, hypochondrium, wrist and abdomen, amenorrhea, dysmenorrhea, puerperal blood stasis, traumatic injury, and swelling and pain.
Radix cyathulae: sweet and slightly bitter taste, neutral nature, entering liver and kidney meridians, has the effects of removing blood stasis and dredging meridians, easing joint movement, inducing diuresis and treating stranguria, and is used for treating amenorrhea, abdominal mass, retained afterbirth, traumatic injury, rheumatic arthralgia, flaccidity of feet, contracture of tendons, hematuria and hematostranguria and other symptoms.
The components mutually support and perform dialectical treatment according to the principle of monarch, minister, assistant and guide compatibility of traditional Chinese medicines, have the effects of promoting blood circulation and regulating qi, dredging collaterals and relieving pain, and clearing heat and promoting diuresis, are effectively used for treating the damp-heat collateral-blocking type chronic prostatitis, and obtain very good beneficial technical effects through experiments, and relevant experimental data are as follows (taking example 1 as an example):
1. general data
In the experimental process, 246 cases of the patients with the damp-heat collateral blocking type chronic prostatitis are observed in experiments, belong to the type III in prostatitis typing of National Institutes of Health (NIH), all cases come from the andrology clinic of 03-2019-2017 in 06 months, and are observed strictly according to the experimental design requirements. 160 cases (prostate navel treatment plaster) of the treatment group of the invention and 80 cases (prostate dredging capsule) of the control group of the invention are treated. 240 patients were in effective cases, 160 of which were aged 18-29 years 53, 30-39 years 56, and 40-50 years 51; 49 cases with the disease course of 2 months to 12 months, 45 cases with the disease course of 13 months to 24 months, 40 cases with the disease course of 25 months to 36 months, and 26 cases with the disease course of 36 months or more. 80 cases of the control group, the age is 18-29 years old, 26 cases are 30-39 years old, 29 cases are 40-50 years old, and 25 cases are 25 cases; 26 cases with the disease course of 2-12 months, 24 cases with the disease course of 13-24 months, 21 cases with the disease course of 25-36 months, and 9 cases with the disease course of 36 months or more. The basic data are shown in Table 1.
TABLE 1 comparison of two sets of pre-treatment basic data (
±s)
| Group of | n | Age (year of old) | Course of disease (moon) | Symptom score |
| Treatment group | 160 | 25.83±4.02 | 7.20±1.99 | 19.16±5.95 |
| Control group | 80 | 28.15±4.91 | 7.80±1.79 | 17.76±6.46 |
Table 1 shows that the two groups have no significant difference (P > 0.05) in age, disease course and symptoms by statistical treatment and are comparable.
2.1 Western medicine diagnosis standard (made by referring to NIH prostatitis classification method) according to 2014 edition of Chinese urinary surgery disease diagnosis and treatment guideline for chronic prostatitis/chronic pelvic pain syndrome: firstly, frequent micturition, urgent micturition, unclean urination and the like are used as main clinical manifestations, and recurrent perineum or pelvic region pain and discomfort are used, and the duration time is more than 3 months; the NIH-CPSI is more than 10 points; ③ prostate massage liquid (EPS) microscopic examination: IIIA type WBC is more than or equal to 10/HP, and the lecithin corpuscle is reduced or disappeared; type IIIB WBC < 10/HP, with a reduced or absent lecithin bodies; bacterial culture negative of prostate massage liquid
2.1.1 symptoms: frequent urination, painful urination, burning and itching urethra, pain around the perineal genital area, the lower abdomen, suprapubic area, and the lumbosacral area of the anus.
2.1.2 digital rectal examination: it may be normal or with an asymmetrical prostate surface, a less smooth surface, uneven texture, tenderness or inflammatory nodules.
2.1.3 EPS-Rt inspection: normal or WBC > 10/HP, with small lecithin bodies reduced or eliminated.
2.2 the standard of traditional Chinese medicine syndrome differentiation is drawn according to the mark of the damp-heat stasis in the diagnosis and treatment guide of the combination of traditional Chinese and western medicine for chronic prostatitis:
the main symptoms are: firstly, pain and discomfort of perineal or pelvic region; ② the scrotum is moist;
the secondary symptoms are as follows: first, frequent, urgent or unclean urination; ② yellow urine, or burning urethra; ③ the tongue is red or dark red, or has petechia, yellow and greasy coating, and wiry and rapid pulse.
The main symptoms are firstly and secondly; or has 1 item of main symptoms I and II and secondary symptoms I, II and III; or with the main symptoms of 1 item and the secondary symptoms of 1 item at the same time, the syndrome can be distinguished as damp-heat stasis type
3.1 inclusion criteria:
meeting the diagnosis standard of the western medicine; ② the patient history is over 3 months, and no other medicine for treating CP/CPPS is taken in the last 1 week, including all western medicine, traditional Chinese medicine or Chinese patent medicine, and no physical or chemical treatment for treating chronic prostatitis is carried out, or the patient is willing to accept 7d of elution period before taking in; fourthly, the traditional Chinese medicine distinguishes the syndrome as damp-heat stasis type; the fifth step of agreeing and signing the informed consent.
3.2 exclusion criteria:
(1) those under 20 years of age or over 55 years of age.
(2) Combined with other acute diseases, acute prostatitis, prostatic hyperplasia, prostate tumor, urethritis, urethral stricture, cystitis, neurogenic bladder, urinary calculus, seminal vesiculitis, epididymitis, tuberculosis of spermatic duct, varicocele, orchitis, lumbosacral bone joint diseases, anorectal diseases, etc.
(3) Patients with serious cardiovascular, brain, liver, kidney or hematopoietic diseases and psychogenic diseases.
(4) A fully compliant volunteer cannot be guaranteed.
4.1 grouping:
the patients are all outpatients, and are divided into two groups according to the inclusion standard by a random number table method according to the sequence of the treatment: 160 cases of the treated group and 80 cases of the control group were observed by a single blind method.
4.2 amounts and dosing regimens
Treatment groups: the Qianlieqiaojing plaster for treating the prostatitis is applied to the navel (Shenque acupoint) before sleeping every night, and is removed when getting up in the morning. 4 weeks is 1 course of treatment.
Control group: the capsule for treating prostatic hyperplasia is orally taken 3 times a day, 4 capsules for treating prostatic hyperplasia at a time. 4 weeks is 1 course of treatment.
4.3 during the treatment and observation period, any other medicines for treating prostatitis, such as antibiotics, alpha-receptor blockers, Chinese medicinal preparations, galenicals and the like, are forbidden, and other treatment schemes are not adopted.
4.4 Observation method:
in both groups of patients, quantitative integration is carried out by a specially-assigned person by using an NIH-CPSI integration table and an EPS-Rt integration table before and after treatment, and main clinical symptoms before and after treatment are recorded. If adverse reactions occur during treatment, the types, the occurrence time, the degree, the treatment measures and the like of the adverse reactions are recorded in detail, whether to terminate experimental observation is determined according to the disease conditions, whether to adopt corresponding treatment measures or not is determined, and the relevance of the adverse reactions and the test drugs is evaluated. Follow-up investigation was conducted on the cases in which the drug was discontinued due to adverse reactions, and the results were recorded in detail.
5.1 NIH-CPSI integration
5.1.1 pain or discomfort
Pain or discomfort (perineum, testicles and scrotum, lower waist, lower abdomen, groin, head of penis, etc. and during or after urination, high sexual tide): the occurrence of 1 item is counted as 1 point, and the non-occurrence is counted as 0 point.
Frequency of pain or discomfort: 0 min never; 1 minute is very small; when the score is 2; 3, frequent dividing; 4 minutes are usual; and 5 points are always.
Average degree of pain or discomfort: the non-pain is counted as 0 point, and the pain is counted as 10 points.
5.1.2 symptoms of urination
Number of inexhaustible after completion of urination: 0 min is absent; 1 is less than 1/5; 2 is less than half; about half in 3; 4, more than half; and 5 points are always.
Number of additional urination within 2 hours after completion of urination: 0 min is absent; 1 is less than 1/5; 2 is less than half; about half in 3; 4, more than half; and 5 points are always.
5.1.3 Effect of symptoms and quality of Life
Symptoms affect the number of frequently done tasks: 0 min is absent; 1 is less than 1/5; 2 is less than half; about half in 3; 4, more than half; and 5 points are always.
Think of the number of symptoms: 0 min is absent; 1 is divided into only one point; 2, dividing into a plurality of parts; 3 into a plurality of parts.
Feeling when spending leisure life: the score of 0 is happy; 1, happy division; score 2 was always satisfactory; 3, dividing each half of satisfaction and dissatisfaction; score 4 is always unsatisfactory; 5 points are not happy; the 6 point is terrible.
5.2 EPS-Rt integration:
the integral method is established according to the chapter of 'turbid semen' in the standard of curative effect for diagnosing traditional Chinese medical symptoms. WBC < 10/HP or lecithin corpuscle full field 0 score; WBC (+) HP or lecithin corpuscle (+) HP counts 1 minute; WBC (+) HP or lecithin corpuscle (+) HP counts 3 points; WBC (+) HP or lecithin corpuscle (+) HP is counted for 6 points; WBCs full field or small lecithin bodies were almost lost for 9 points.
5.3 safety index detection
Mainly observe three major routine of blood, excrement and urine before and after treatment, liver and kidney functions and electrocardiogram.
The traditional Chinese medicine disease diagnosis curative effect standard is referred to for drawing up 'Jingzhuo', the curative effect is evaluated by NIH-CPSI integral and EPS-Rt integral, and the calculation method comprises the following steps: [ (pre-treatment score-post-treatment score)/pre-treatment score ]. times 100%
And (3) healing: the NIH-CPSI integral is reduced by more than 90 percent, and the EPS-Rt integral is reduced by more than 90 percent.
The effect is shown: the NIH-CPSI integral is reduced by 60-89%, and the EPS-Rt integral is reduced by 60-89%.
The method has the following advantages: the NIH-CPSI integral is reduced by 30-59 percent, and the EPS-Rt integral is reduced by 30-59 percent.
And (4) invalidation: the NIH-CPSI integral is reduced by less than 30 percent, and the EPS-Rt integral is reduced by less than 30 percent.
The healing, the obvious effect and the effective three are all effective, and the total effective rate is calculated according to the effective rate
7 statistical treatment
The data is processed by SPSS11.0 for Windows system product analysis software, the metering data is tested by t, the counting and grade data are analyzed by Ridit and chi square2) And (6) checking.
7.1 Total therapeutic Effect
In the experimental observation process, 4 cases in the treatment group were removed (excluded), 2 cases in the control group were removed (excluded), and the cases in the treatment group (4) and the control group (2) were removed because the treatment effect and safety evaluation were not affected by the administration of the drug according to the regulations. The final statistical treatment results are shown in table 2.
Table 2 two groups of comparative examples of clinical efficacy (%)
| Group of | n (human) | Recovery (human) | Display effect (human) | Effective (human) | Invalid (human) | Total effective rate |
| Treatment group | 156 | 46(29.5%) | 51(32.7%) | 42(26.9%) | 17(10.9%) | 89.1% |
| Control group | 78 | 8(10.3%) | 23(29.5%) | 26(33.3%) | 21(26.9%) | 73.1% |
Note: compared with the control group, the two groups have significant difference in curative effect, P is less than 0.05
7.2 NIH-CPSI integral comparison
Table 3 shows that, according to t-test, the two groups of NIH-CPSI scores had no significant difference (P > 0.05) compared before treatment, and had significant difference after treatment (P < 0.05 ═ compared before and after treatment, and the two groups had significant difference P < 0.05.
TABLE 3 two sets of NIH-CPSI integral comparisons: (
±s)
| Group of | n | Before treatment | After treatment |
| Treatment group | 156 | 19.38±2.47 | 6.08±2.04△* |
| Control group | 78 | 18.25±1.12 | 9.90±2.57* |
Note: compared with the control group, the delta P is less than 0.05
Comparison before and after treatment, P < 0.05
7.3 EPS-Rt integral comparison
Table 4 shows that, by t test, the two groups of EPS-Rt scores have no significant difference (P is more than 0.05) compared before treatment and have significant difference (P is less than 0.05) compared after treatment. The two groups have significant difference (P is less than 0.05) compared before and after treatment. Both groups are shown to improve the EPS-Rt score, but the treatment group is obviously superior to the control group.
TABLE 4 two sets of EPS-Rt integral comparisons: (
±s)
| Group of | n | Before treatment | After treatment |
| Treatment group | 156 | 5.55±2.29 | 2.65±1.10△* |
| Control group | 78 | 4.75±1.97 | 3.45±1.23* |
Note: compared with the control groupIn comparison, the method has the advantages that,△p is less than 0.05; compared before and after the treatment,*P＜0.05
7.4 adverse events record
In all observation cases, 6 treatment groups begin to use the prostate navel treatment patch, local skin itch and eruption appear, and patients disappear after the application time is shortened, and the treatment is not affected; similar conditions in 2 control groups did not affect treatment. No obvious abnormality is found in the functions of heart, liver and kidney.
The same and similar results are obtained when the experiment is carried out on the example 1 and other examples simultaneously, which shows that the prescription is scientific and reasonable, the curative effect is stable and reliable, and the detailed description is omitted.
8. Conclusion
The etiology of chronic prostatitis (CP/CPPS) is complex, the pathogenesis is not completely clear, and the chronic prostatitis can be caused by the combined action of multiple factors such as pathogen infection, inflammation, urine reflux, abnormal activity of pelvic floor nerve and muscle, abnormal immunity, psychopsychological factors and the like. At present, no ideal therapeutic medicine exists. In the traditional Chinese medicine, CP/CPPS is classified into the categories of turbid semen, stranguria and the like, the pathogenesis of chronic prostatitis plays an important role in dampness, heat and blood stasis, the key points of the pathogenesis of chronic prostatitis are that damp-heat evil toxin is infected, pathogenic factors fall down along meridians, the evil toxin stays in the seminal compartment (in prostate), gland tissues are damaged, the internal environment of the gland is damaged, the turbid stasis in the gland is not smoothly discharged, the gland tissues are proliferated, focus fibrosis is caused, the inflammation infiltration, gland edema and gland hyperemia are caused, and the fibrosis is the microscopic pathological basis of the dampness-heat collateral blocking type chronic prostatitis considered as 'stasis and dampness-heat stagnation' in the traditional Chinese medicine.
The symptom of the III type chronic prostatitis mostly takes pelvic cavity region pain as a common symptom, the disease course is long, the chronic prostatitis attacks repeatedly, stasis is caused when the patient suffers from long-term illness, and the chronic prostatitis enters collaterals, so that the basic pathogenesis of the chronic prostatitis is that dampness and heat are accumulated and the veins are blocked. According to the pathogenesis characteristics, the theory of collateral diseases is taken as a guide, and the treatment method is a method for promoting blood circulation to remove meridian obstruction and detoxifying and clearing the heat, and the prescription is selected. Based on the theory of "external treatment, i.e. internal treatment, and external treatment, i.e. internal treatment", in TCM, the disease is treated by navel therapy.
The umbilicus, also known as Shenque acupoint in TCM, is the collection of meridians and collaterals, the sea of meridian qi. Just as the book of Su Wen & Ji Lun: the Shenque point is the root of life, the congenital pedicel, the acquired qi house, which is located between the middle-jiao and the lower-jiao, adjacent to the spleen, stomach and kidney, and is the location of the movement of qi between the kidneys. The Shenque point is communicated with the channels and collaterals of the whole body and connected with the viscera, and the Shenque application not only can stimulate the qi of the channels and collaterals and regulate qi and blood, but also can play an obvious pharmacological action through the local absorption of the medicine. The navel therapy can regulate qi and blood, promote blood circulation, dredge collaterals, regulate viscera, and promote diuresis and heat.
Therefore, the navel treatment medicine adopts artificial musk, frankincense, myrrh, scutellaria baicalensis, wine-processed rhubarb, golden cypress, radix sophorae flavescentis, scalding leech, mole cricket, tangerine seed, vinegar rhizoma corydalis and medicinal cyathula root, and the compatibility adopts monarch, minister, assistant and guide, and the components support each other to perform disease differentiation treatment. The musk is used for dredging collaterals and relieving pain, the scutellaria is used for detoxifying and clearing damp-heat, and the musk and the scutellaria are used as monarch drugs; frankincense, myrrh, scalded leech and mole cricket activate blood and remove blood stasis, radix sophorae flavescentis, golden cypress and wine rhubarb clear away heat and toxic materials, and the wine rhubarb has the function of activating blood and removing blood stasis and is used as ministerial drugs; the lychee seed is used as an adjuvant drug for regulating qi and soothing liver, and the vinegar rhizoma corydalis is used for activating blood and relieving pain, and the lychee seed and the rhizoma corydalis are warm in nature and can prevent the bitter and cold properties of the medicaments such as the scutellaria baicalensis, the rheum officinale and the radix sophorae flavescentis; cyathula root, radix Cyathulae has the actions of activating blood and resolving stasis, and guiding the drug directly to the disease site, so it is used as a guiding drug. The formula has the advantages of excellent medicine selection and precise compatibility, has the effects of promoting blood circulation and regulating qi, dredging collaterals and relieving pain, and clearing heat and promoting diuresis, and is effectively used for treating damp-heat collateral blocking type chronic prostatitis.
The test result shows that the curative effect of the treatment group (the prostate navel treatment plaster) is obviously better than that of the control group compared with the control group, and the difference has statistical significance; the treatment group was also superior to the control group in the improvement of NIH-CPSI score and EPS-Rt score. Meanwhile, no obvious adverse reaction is found in the treatment process of the plaster, which shows that the plaster for treating the prostatitis by the navel therapy has definite curative effect and better safety, the curative effect is as high as more than 89%, and the plaster has good clinical practical application value, is worthy of clinical popularization and application, and has obvious economic and social benefits.
Claims (4)
1. The navel treatment medicine for treating the damp-heat collateral obstruction type chronic prostatitis is characterized by comprising the following components in parts by weight: 0.2-0.3g of artificial musk, 8-12g of frankincense, 8-12g of myrrh, 10-14g of scutellaria baicalensis, 10-14g of wine-processed rhubarb, 10-14g of golden cypress, 10-14g of sophora flavescens, 2.5-3.5g of scalded leech, 2.5-3.5g of mole cricket, 13-17g of tangerine seed, 18-22g of vinegar rhizoma corydalis and 11-17g of medicinal cyathula root, wherein the artificial musk is firstly crushed into fine powder for later use; extracting Scutellariae radix, Olibanum, Myrrha, rhizoma corydalis processed with vinegar, and radix et rhizoma Rhei as first mixture with 70% ethanol at room temperature for 2 times, wherein the amount of ethanol added is 4-6 times of the first mixture weight each time, and each time is 2 hr, mixing extractive solutions, recovering ethanol, and concentrating to obtain first fluid extract with relative density of 1.30-1.35 at 60 deg.C; taking cortex phellodendri, radix sophorae flavescentis, leech, mole cricket, tangerine seed and radix cyathulae as a second mixture, adding water to extract for 2 times at room temperature, adding water for 2 hours each time, wherein the amount of water added is 6-8 times of the weight of the second mixture, combining decoction, filtering, concentrating to a second clear paste with the relative density of 1.30-1.35 at 60 ℃, uniformly mixing the fine powder of artificial musk, the first clear paste and the second clear paste, and adding polyvinyl alcohol and azone according to a conventional method to prepare the patch.
2. The navel treatment medicine for treating dampness-heat collateral obstruction type chronic prostatitis according to claim 1, which is prepared from the following raw materials by weight: 0.25g of artificial musk, 10g of frankincense, 10g of myrrh, 12g of scutellaria baicalensis, 12g of wine-processed rhubarb, 12g of phellodendron, 12g of sophora flavescens, 3g of scalded leech, 3g of mole cricket, 15g of tangerine seed, 20g of vinegar rhizoma corydalis and 15g of medicinal cyathula root, wherein the artificial musk is firstly crushed into fine powder for standby; extracting Scutellariae radix, Olibanum, Myrrha, rhizoma corydalis processed with vinegar, and radix et rhizoma Rhei with 70% ethanol at room temperature for 2 times, wherein the first ethanol is 6 times of the first mixture by weight for 2 hr, and the second ethanol is 4 times of the first mixture by weight, mixing the two ethanol extractive solutions, recovering ethanol, and concentrating to obtain first fluid extract with relative density of 1.32 at 60 deg.C; cortex Phellodendri, radix Sophorae Flavescentis, Hirudo, Gryllotalpa, semen Citri Reticulatae, and radix Cyathulae as second mixture, adding water, extracting at room temperature for 2 times, the first time adding water 8 times the weight of the second mixture for 2 hr, the second time adding water 6 times the weight of the second mixture for 2 hr, mixing the two water extractive solutions, filtering, concentrating to obtain second fluid extract with relative density of 1.32 at 60 deg.C, mixing the fine powder of artificial Moschus, the first fluid extract, and the second fluid extract, and adding polyvinyl alcohol and azone to make into patch.
3. The navel treatment medicine for treating dampness-heat collateral obstruction type chronic prostatitis according to claim 1, which is prepared from the following raw materials by weight: 0.22g of artificial musk, 11g of frankincense, 9g of myrrh, 13g of scutellaria baicalensis, 11g of wine-processed rhubarb, 13g of phellodendron, 11g of sophora flavescens, 3.3g of scalded leech, 2.7g of mole cricket, 16g of tangerine seed, 19g of vinegar rhizoma corydalis and 16g of medicinal cyathula root, wherein the artificial musk is firstly crushed into fine powder for standby; extracting Scutellariae radix, Olibanum, Myrrha, rhizoma corydalis processed with vinegar, and radix et rhizoma Rhei with 70% ethanol at room temperature for 2 times, wherein the amount of ethanol added is 5 times of the first mixture weight, and the extraction time is 2 hr, mixing the two ethanol extractive solutions, recovering ethanol, and concentrating to obtain first fluid extract with relative density of 1.33 at 60 deg.C; extracting cortex Phellodendri, radix Sophorae Flavescentis, Hirudo, Gryllotalpa, semen Citri Reticulatae, and radix Cyathulae with water at room temperature for 2 times, each time adding water 7 times the weight of the second mixture, each time extracting for 2 hr, mixing the two water extractive solutions, filtering, concentrating to obtain second fluid extract with relative density of 1.33 at 60 deg.C, mixing the fine powder of artificial Moschus, the first fluid extract, and the second fluid extract, adding polyvinyl alcohol and azone, and making into patch.
4. The navel treatment medicine for treating dampness-heat collateral obstruction type chronic prostatitis according to claim 1, which is prepared from the following raw materials by weight: 0.28g of artificial musk, 9g of frankincense, 11g of myrrh, 11g of scutellaria baicalensis, 13g of wine rhubarb, 11g of golden cypress, 13g of radix sophorae flavescentis, 2.7g of scalded leech, 3.3g of mole cricket, 14g of tangerine seed, 21g of vinegar rhizoma corydalis and 12g of medicinal cyathula root, wherein the artificial musk is firstly crushed into fine powder for later use; extracting Scutellariae radix, Olibanum, Myrrha, rhizoma corydalis processed with vinegar, and radix et rhizoma Rhei with 70% ethanol at room temperature for 2 times, wherein the first ethanol is 6 times of the first mixture by weight for 2 hr, and the second ethanol is 4 times of the first mixture by weight, mixing the two ethanol extractive solutions, recovering ethanol, and concentrating to obtain first fluid extract with relative density of 1.35 at 60 deg.C; extracting cortex Phellodendri, radix Sophorae Flavescentis, Hirudo, Gryllotalpa, semen Citri Reticulatae, and radix Cyathulae as second mixture with water at room temperature for 2 times, the first time with water amount 8 times of the second mixture for 2 hr, the second time with water amount 6 times of the second mixture for 2 hr, mixing the two water extractive solutions, filtering, concentrating to obtain second fluid extract with relative density of 1.35 at 60 deg.C, mixing the fine powder of Moschus, the first fluid extract, and the second fluid extract, and adding polyvinyl alcohol and azone to make into patch.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010922464.3A CN111973678B (en) | 2020-09-04 | 2020-09-04 | Navel treatment medicine for treating damp-heat collateral obstruction type chronic prostatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010922464.3A CN111973678B (en) | 2020-09-04 | 2020-09-04 | Navel treatment medicine for treating damp-heat collateral obstruction type chronic prostatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111973678A true CN111973678A (en) | 2020-11-24 |
| CN111973678B CN111973678B (en) | 2021-12-21 |
Family
ID=73447686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010922464.3A Expired - Fee Related CN111973678B (en) | 2020-09-04 | 2020-09-04 | Navel treatment medicine for treating damp-heat collateral obstruction type chronic prostatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111973678B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115154528A (en) * | 2022-07-15 | 2022-10-11 | 陕西方浩生物科技有限公司 | A Chinese medicinal patch for external use for treating prostatitis and prostatic hyperplasia |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1255341A (en) * | 1998-11-27 | 2000-06-07 | 李德明 | Exterior-applied Chinese medicine and medical health-care underpants for preventing and treating piles |
| CN101791389A (en) * | 2009-02-03 | 2010-08-04 | 漆瑞民 | Perineum medicine membrane underpants for treating prostatic hyperplasia and chronic prostatitis, perineum medicine membrane patch and preparation method |
| CN102091276A (en) * | 2011-01-17 | 2011-06-15 | 赵献民 | Traditional Chinese medicine composition for treating prostatic hypertrophy and preparation method thereof |
| CN104056203A (en) * | 2014-07-03 | 2014-09-24 | 孙自学 | External-use traditional Chinese medicine for treating dampness and hotness obstruction type chronic prostatitis |
-
2020
- 2020-09-04 CN CN202010922464.3A patent/CN111973678B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1255341A (en) * | 1998-11-27 | 2000-06-07 | 李德明 | Exterior-applied Chinese medicine and medical health-care underpants for preventing and treating piles |
| CN101791389A (en) * | 2009-02-03 | 2010-08-04 | 漆瑞民 | Perineum medicine membrane underpants for treating prostatic hyperplasia and chronic prostatitis, perineum medicine membrane patch and preparation method |
| CN102091276A (en) * | 2011-01-17 | 2011-06-15 | 赵献民 | Traditional Chinese medicine composition for treating prostatic hypertrophy and preparation method thereof |
| CN104056203A (en) * | 2014-07-03 | 2014-09-24 | 孙自学 | External-use traditional Chinese medicine for treating dampness and hotness obstruction type chronic prostatitis |
Non-Patent Citations (3)
| Title |
|---|
| 孙自学,等: "慢性前列腺炎的中医诊疗思路探析", 《辽宁中医杂志》 * |
| 常松山,等: "前列康栓治疗慢性前列腺炎60例临床观察", 《河南中医》 * |
| 肖远辉,等: "中药综合疗法治疗慢性前列腺炎46例疗效观察", 《新中医》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115154528A (en) * | 2022-07-15 | 2022-10-11 | 陕西方浩生物科技有限公司 | A Chinese medicinal patch for external use for treating prostatitis and prostatic hyperplasia |
| CN115154528B (en) * | 2022-07-15 | 2023-06-20 | 陕西方浩生物科技有限公司 | A Chinese medicinal patch for external use for treating prostatitis and prostatic hyperplasia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111973678B (en) | 2021-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100531768C (en) | Medicament for treating chronic prostatitis and prostatic hyperplasia | |
| CN104523865A (en) | Medicine for treating breast diseases | |
| CN112138054A (en) | Chinese herbal medicine preparation for treating hemorrhoids and preparation method thereof | |
| CN103520680A (en) | Traditional Chinese medicine for treating acute heart failure | |
| CN101757402B (en) | Traditional Chinese medicine composition for treating uroschesis and prostatitis and preparation method thereof | |
| CN111973678B (en) | Navel treatment medicine for treating damp-heat collateral obstruction type chronic prostatitis | |
| CN104547698A (en) | Traditional Chinese medicine preparation for painless treatment of haemorrhoids and preparation method thereof | |
| CN111135239A (en) | Traditional Chinese medicine enema for treating Crohn's disease | |
| CN106421666A (en) | Pharmaceutical composition for treating liver depression and kidney deficiency type premature ovarian failure | |
| CN103432485B (en) | Chinese medicinal preparation for treating urinary calculus and preparation method | |
| CN104056105B (en) | Traditional Chinese medicinal decoction for treating prostatitis | |
| CN105920488A (en) | Traditional Chinese medicine leading-in liquid for coordinating with acusector and treating overactive bladder | |
| CN105148135A (en) | Traditional Chinese medicine preparation for treating chronic prostatitis | |
| CN104825991A (en) | Traditional Chinese medicine preparation for alcoholism induced mental disorder, and preparation method thereof | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN100493521C (en) | Medicine for treating venereal disease and production method | |
| CN102302639B (en) | Traditional Chinese medicine composition for treating retention of urine | |
| CN102824573B (en) | Medicine for treating prostatic diseases | |
| CN105999116B (en) | Traditional Chinese medicine enema prescription for treating chronic pelvic pain | |
| CN108403974B (en) | Traditional Chinese medicine composition for treating calculus | |
| CN105412698A (en) | Traditional Chinese medicine composition for treating chronic prostatitis and preparation process thereof | |
| CN104825729A (en) | Traditional Chinese medicine preparation for treating prostatitis | |
| CN112107643A (en) | Chinese medicinal compound oral preparation for treating chronic nonbacterial prostatitis and preparation process thereof | |
| CN104840897A (en) | Traditional Chinese medicine for treating prosopalgia | |
| CN103223130A (en) | Traditional Chinese medicinal composition for treating prostatic hyperplasia and preparation method of preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20211221 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |